Lazard's pharmaceuticals research team holds analyst/industry conference call Pharmaceuticals Research Team discusses BioMarin's BMN-701 for the treatment of Pompe Disease on an Analyst/Industry conference call to be held on February 28 at 2 pm.
NHS to wait on NICE to make call on PTC Therapeutics, BioMarin drugs NHS England has set out its planned investment decisions for certain specialized services as part of its annual commissioning round. NHS England has agreed with the recommendations from CPAG that final funding decisions on the following two treatments should be made after NICE has concluded its Highly Specialized Technology Appraisal process: BioMarin Pharmaceutical's (BMRN) Vimizim for Morquio A Syndrome and PTC Therapeutics' (PTCT) Translarna for Duchenne muscular dystrophy. The decisions on those two drugs came among 39 proposed new investments that the group said were "carefully considered against the principles NHS England follows when making investment decisions." Reference Link
Sarepta NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin's (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin.